TAS-102 plus bevacizumab in metastatic colorectal cancer - Authors' reply

Lancet Oncol. 2020 May;21(5):e227. doi: 10.1016/S1470-2045(20)30232-1.

Authors

Per Pfeiffer¹, Sören Möller², Stine Braendegaard Winther³, Camilla Qvortrup⁴

Affiliations

¹ Department of Oncology, Odense University Hospital, Odense 5000, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: per.pfeiffer@rsyd.dk.
² Odense Patient Data Explorative Network, Odense University Hospital, Odense 5000, Denmark.
³ Department of Oncology, Odense University Hospital, Odense 5000, Denmark.
⁴ Department of Oncology, Rigshospitalet, Copenhagen, Denmark.

PMID: 32359492
DOI: 10.1016/S1470-2045(20)30232-1

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Bevacizumab
Drug Combinations
Humans
Pyrrolidines
Rectal Neoplasms*
Thymine
Trifluridine*
Uracil / analogs & derivatives

Substances

Drug Combinations
Pyrrolidines
trifluridine tipiracil drug combination
Bevacizumab
Uracil
Thymine
Trifluridine